Thrombocytopenia following myelotoxic therapy is a common problem and when severe (Ͻ20 000/l) can lead to severe morbidity and mortality. Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the differentiation of bone marrow stem cells into megakaryocyte progenitor cells, induces the expression of megakaryocyte differentiation markers, promotes megakaryocyte proliferation, polyploidization and, ultimately, the formation of increased numbers of platelets in the circulation. TPO has now been produced by recombinant technology and has entered clinical trials. This open label phase I study was designed to determine the safety, tolerance and pharmacokinetics of recombinant thrombopoietin (rhTPO) when administered to patients after undergoing highdose chemotherapy followed by autologous bone marrow transplantation. rhTPO was administered intravenously by bolus injection at doses ranging from 0.3 to 4.8 g/kg/day every 3 days to 30 patients and 0.6 g/kg daily to three patients. rhTPO was begun the day after marrow infusion and continued until platelet recovery to Ͼ20 000/l. G-CSF was concomitantly administered to promote myeloid recovery. Serious adverse events or neutralizing antibodies to rhTPO were not observed during the study. Median platelet recovery after ABMT was 19 days (range, 11-41). Neither the dose nor the schedule of rhTPO appeared to have any impact upon the time course of platelet recovery. In this phase I study, rhTPO was found to be well tolerated without the development of neutralizing antibodies and without compromising neutrophil recovery. Platelet recovery was similar for all doses studied warranting further evaluation in phase II and III trials designed to test for platelet recovery efficacy. Bone Marrow Transplantation (2001) 27, 261-268.
Thrombocytopenia following myelotoxic therapy is a common problem and can lead to substantial morbidity and mortality when severe (Ͻ10 000-20 000/l). Other detrimental events such as transfusion reaction, alloimmunization, infection, the necessity of frequent outpatient followup and the time to return to normal quality of life may also depend on the duration of severe thrombocytopenia.
Thrombocytopenia-associated bleeding is treated with transfusions of platelets obtained from volunteer blood donors. 1, 2 There is a lack of uniformity about what platelet count warrants prophylactic transfusion. Current practice is to maintain the platelet count above 10 000-20 000/l, especially with active bleeding or during periods of treatment-related morbidity. However, recent studies have suggested that many patients will be able to tolerate the lower platelet threshold for transfusion or can be transfused only when febrile or actively bleeding. [3] [4] [5] [6] Patients requiring invasive procedures must sustain substantially higher platelet levels.
Patients undergoing dose-intensive or myeloablative anti-neoplastic therapy will universally develop severe and sustained thrombocytopenia. 7 Autologous hematopoietic stem cell transplantation as an adjunct to dose-intensive therapy, while hastening recovery and ultimately restoring hematopoiesis, is still associated with profound thrombocytopenia. [8] [9] [10] The duration of severe thrombocytopenia is the shortest with the transplantation of peripherally derived stem cells (PBSC) mobilized by chemotherapy and/or cytokine(s). The median time from PBSC transplantation (PBSCT) to platelet recovery is in the order of 10-13 days compared to more than 1 week longer with stem cells directly harvested from marrow. 11 Stem cells which are manipulated ex vivo are associated with more prolonged thrombocytopenia compared with unmanipulated cells from the same source. 12 The number of stem cells inversely affects the duration of thrombocytopenia. 13, 14 This relationship is important since approximately one quarter of patients who undergo autologous mobilization of peripheral stem cells mobilize low numbers of stem cells necessitating multiple leukaphereses. In fact, some patients or even normal allogeneic donors do not mobilize at all, or mobilize so poorly, that they require direct bone marrow harvesting to assure an adequate graft. 15, 16 Bone Marrow Transplantation Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the differentiation of bone marrow stem cells into megakaryocyte progenitor cells, induces the expression of megakaryocyte differentiation markers, promotes megakaryocyte proliferation and polyploidization and, ultimately, the formation of increased numbers of platelets in the circulation. [17] [18] [19] Additionally, there is enhanced proliferation of early erythroid and myeloid progenitors. 20 Both the full length intact molecule (TPO 1-332) and peptide fragments derived from the amino terminus (TPO 1-153) are capable of differentiating progenitor cells into megakaryocytes and increasing the platelet count following in vivo administration. 21 TPO is the most effective cytokine to hasten recovery from thrombocytopenia in in vitro and in vivo models of severe thrombocytopenia. [22] [23] [24] Recombinant human thrombopoietin (rhTPO; Genentech, South San Francisco, CA, USA; Pharmacia and Upjohn, Bridgewater, CT, USA) has been entered into a broad array of clinical trials in the setting of myelosuppressive and myeloablative cytotoxic therapy. Other forms of the molecule have also been evaluated in clinical studies. [25] [26] [27] [28] [29] The phase I study we are now reporting was conducted to evaluate the safety, pharmacokinetics and potential activity of rhTPO in reducing the time to platelet transfusion independence after high-dose chemotherapy with autologous bone marrow transplantation (ABMT) in women with breast cancer. Issues planned for evaluation by this study included the impact of rhTPO on G-CSF enhanced neutrophil recovery, pharmacokinetic evaluation of dose and schedule, formation of neutralizing antibody against rhTPO and other safety issues. ABMT (as opposed to PBSCT) was used to facilitate the observation of the effect of TPO on the duration of thrombocytopenia since platelet recovery after ABMT is more prolonged compared with PBSCT and since no adverse impact upon overall outcome was anticipated using bone marrow. It was hoped that this phase I study would also suggest a dose of rhTPO to be used in more definitive phase II/III studies to test for platelet recovery efficacy.
Methods

Objectives
The primary objectives of this phase I study were to determine the safety, tolerance and pharmacokinetics of intravenously (i.v.) administered rhTPO in patients following ABMT. The secondary objectives were to evaluate biologic activity by the time to platelet recovery and transfusion independence and to determine the maximally tolerated or biologically active dose in the absence of dose-limiting toxicity.
Patient eligibility
Patients with advanced breast cancer (stage III/IV) were eligible if they had a Zubrod performance status Ͻ2, were age у18 years old, and had adequate hematopoietic and organ function (bone marrow function: WBC у3000/l, absolute neutrophil count у1500/l, platelet count between 100 000/l and 500 000/l, and a minimum marrow mononuclear cell harvest of 2 × 10 8 /kg for transplantation; hepatic function: SGOT (AST)/SGPT (ALT) Ͻ3 × normal and bilirubin Ͻ1.5 × normal; renal function: creatinine Ͻ1.5 × normal; cardiac function: ejection fraction of у50% (±5%) by echocardiogram or MUGA scan; pulmonary function: (DLCO) of Ͼ50% of predicted. A target of 2 × 10 8 /kg total nucleated cells was the minimum target for adequacy of marrow collection which was the standard of care at the time of the trial. Marrow CD34 + cell content was measured but not used as an eligibility criterion. Patients were deemed ineligible if there was any history of a functional platelet disorder such as idiopathic thrombocytopenic purpura; a history of ischemic, thrombotic, or embolic phenomena; an uncontrollable cardiac dysrhythmia; prior therapy with mitomycin C or a nitrosourea; three or more prior chemotherapy regimens; prior myeloablative therapy with ABMT or PBSCT; a history of malignant disease within the central nervous system or the bone marrow; use of any marrow purging; or any experimental agents within the 4 weeks prior to beginning this trial.
Study design and rhTPO administration
This was a multicenter phase I, non-randomized, openlabel, dose escalation trial of multiple intravenous doses of rhTPO in patients following ABMT. The study was IRB approved at each treatment center and all patients gave informed consent. Patients were assigned to six dosing regimens of rhTPO (Table 1 ). All patients received their marrow reinfusion on day 0, and began rhTPO 1 day later (day 1). No intra-patient dose-escalation was permitted. rhTPO, based on actual baseline body weight, was administered intravenously by bolus injection every 3 days for a maximum of 10 injections (dose kevels 1-4 and 6), or daily for a maximum of 21 injections (dose level 5), or until the untransfused platelet count was Ͼ75 000/l for at least two consecutive measurements separated by at least 24 h. The study period consisted of the 35 days following the initial rhTPO administration with follow-up 1 month later. 
Cytotoxic treatment
After harvest and cryopreservation (using standard methodology) of unmanipulated autologous bone marrow, patients were treated with cyclophosphamide 180 mg/kg (60 mg/kg/day for 3 consecutive days), thiotepa 900 mg/m 2 (300 mg/m 2 for 3 consecutive days) with or without carboplatin 600 mg/m 2 , followed in 3 days by infusion of rapidly thawed marrow cells (day 0). All patients received G-CSF subcutaneously at a dose of 5 g/kg beginning on day 1 until the absolute neutrophil count was maintained Ͼ500/l for 2 consecutive days. Platelets (single donor or random pooled) were transfused for a morning platelet count Ͻ20 000/l or whenever clinically indicated for active bleeding. At the time of this study, this platelet transfusion trigger was the standard of practice.
Statistical analysis and definitions
The study was prospectively designed to use the Jonkheere-Terpstra test for a decreasing trend in time to platelet transfusion independence with increasing dose. 30, 31 Test statistics were compared to quartiles of the tabled exact null distribution. 32 These nonparametric tests were appropriate for the study endpoint with a small sample size and minimal censoring. Dose and schedule cohorts were planned to consist of approximately six subjects per dosing level for a total of 36 subjects for the regimens. This sample size was chosen to achieve adequate power (Ͼ80%) for the doseresponse trend test in the case of a strong decreasing trend in time to platelet recovery (linear decline in median days from 23 at 0.3 mg/kg to 13 at 4.8 mg/kg) and a constant or decreasing variance with increasing dose level. For endpoints such as occurrence of a specific adverse event or formation of antibodies to rhTPO, this sample size guaranteed at least 80% power to detect one or more events among the six subjects if the true event probability is у24%. Toxicity was graded using the NCI Common Toxicity Criteria with serious adverse events prospectively defined as grade IV or V.
To facilitate comparison with other trials, platelet recovery was defined as the first day of 3 consecutive days of an untransfused platelet count у20 000/l (definition 1). and more rigorously as the first of у2 consecutive days of untransfused platelet counts у20 000/l with the second count greater than or equal to the preceding value (definition 2). Subjects not achieving platelet recovery by the end of the study were censored on the day of the last measured platelet count. Neutrophil recovery was defined as the first of 2 consecutive days with an absolute neutrophil count у500/l. rhTPO rhTPO was provided by Genentech Inc as a sterile liquid ready for parenteral administration in 3 ml glass vials in preservative-free buffer. rhTPO was shipped on wet ice, and stored refrigerated at 2-8°C. Sites were instructed to avoid freezing, vigorous agitation, exposure to bright light or using the vials beyond the stamped expiration date.
Bone Marrow Transplantation rhTPO antibody assay and serum rhTPO measurements
Serum samples were screened for the presence of antirhTPO antibodies using a panel of four assays: ELISA based on full-length rhTPO molecule; ELISA based on a truncated rhTPO molecule; ELISA based on blocking the binding of rhTPO to the c-mpl receptor; bioassay based on inhibition of an rhTPO-dependent cell line. 33 Two baseline samples were collected prior to infusion of rhTPO followed by weekly sampling until day 35 and then 1 month later (day 60). Serum rhTPO concentrations were measured by an ELISA method using the recombinant c-mpl receptor as a coat with lower limit of detection of 0.078 ng/ml. Samples were obtained just prior to the first infusion and at the following time points after administration: 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h and 48 h. On the 4th, 7th, 10th, 13th, 16th, 19th, 22nd, 25th and 28th day of administration samples were obtained prior to and 5 min after rhTPO administration.
Results
Patients
A total of 33 female patients were enrolled. The median age was 48.2 years (range 24-61) with 29 Caucasians, two African-Americans, and two Hispanics enrolled. Twentyseven patients had a PS of 0, and six had a PS of 1. The median number of months since diagnosis was 9.0 (range, 3.6-124). Seventeen patients had received two prior regimens of chemotherapy, while 16 had received only one prior regimen; nine patients had also received one prior course of radiotherapy. Twenty-three of the patients were treated with cyclophosphamide, thiotepa and carboplatin and the remaining 10 received cyclophosphamide and thiotepa. The median number (range) of marrow harvested total nucleated cells × 10 8 /kg and CD34 × 10 6 /kg was 2.25 (0.20-193.7) and 2.82 (0.00-13.4), respectively. Comparison between treatment groups (ANOVA) of the TNC and CD34 + content of the harvest marrow was not significantly different (P = 0.06 and P = 0.59, respectively).
rhTPO dosing
The first subject began dosing on 7 May, 1996 and the last subject completed dosing on 4 March, 1997. Seven patients were entered on each of the first three dose levels, three patients on each of the next two levels and six on the highest dose level (Table 1 ). This variance from the scheduled six patients per level was due to the concomitant entrance of patients at multiple centers during the early part of the trial and the desire to treat patients at the highest dose level during the later part of the study. A total of 225 doses of rhTPO were delivered on the every third day schedule with a median of seven doses/patient administered with the exception of the 4.8 g/kg dose level, where a median of 7.5 doses/patient were administered (Table 1) . A total of 59 doses were administered on the 0.6 g/kg daily schedule, with a median of 19 doses/patient.
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Toxicity
All patients experienced adverse events within the spectrum of toxicities that are observed after myeloablative therapy. No pattern or unanticipated toxicity was perceived to be related to the administration of rhTPO. A total of 14 serious adverse events were observed in 10 patients; none was deemed by the investigators to be possibly or probably related to rhTPO administration. There was one death on study, a 52-year-old female died of multi-system organ failure on study day 20 secondary to toxicities of the preparative regimen, having received seven doses of rhTPO. The overall death rate during the study period was 3% (95% confidence interval of 0.5-15%). One patient experienced a subdural hematoma on study day 16 with a platelet count of 25 000/l and was treated with platelet transfusions followed by surgical evacuation and recovered. One patient experienced a perceived delayed neutrophil recovery (day 28) which was felt to be secondary to a human herpes virus 6 infection. No patient experienced any thrombotic event or developed veno-occlusive disease of the liver.
In addition to the patient expiring from cytotoxic regimen-related toxicity, one other patient did not complete full rhTPO dosing, This patient discontinued study drug after seven doses due to an anxiety event. During the study and follow-up period, five patients experienced eight non-serious events regarded as possibly or probably related to rhTPO administration. One episode of asthenia was categorized as severe grade III, the remaining events were graded as mild or moderate grade I-II. These included rash (n = 3), back pain, chills, myalgias, and vasodilatation with facial flushing (n = 1 each). None of these side-effects had any influence upon subsequent dose administration. There were no clinically significant change in vital signs or findings on physical examination related to rhTPO administration.
Trend analysis was performed at the completion of this study for the following parameters: platelet and neutrophil counts, hemoglobin, AST, ALT, total bilirubin, serum creatinine, and blood urea nitrogen (BUN). No significant trends in the occurrence, extent, or distribution of abnormal values (ie values outside of normal ranges) were apparent for any of the laboratory parameters.
Three patients were noted to have activity in the ELISA based on full-length rhTPO either at screening (prior to receiving any rhTPO) or at some later time point. No patient at any time point was positive in the ELISA assay based on truncated rhTPO, the ELISA c-mpl blocking assay, or in the bioassay which detects neutralizing antibody.
rhTPO pharmacokinetics
Prior to rhTPO administration, measurable TPO levels were found in all patients. The mean baseline TPO level was 0.96 ng/ml (range, 0.14-2.36 ng/ml). Mean baseline TPO concentration for each dosing level was 1.01 (±0.68), 0.80 (±0.44), 1.07 (±0.37), 0.77 (±0.57) and 1.17 (±0.64) ng/ml, respectively for patients receiving 0.3, 0.6, 1.2, 2.4 and 4.8 g/kg every third day and 0.77 (±0.62) ng/ml for subjects receiving 0.6 g/kg daily.
Selected pharmacokinetic parameters are noted in Table 2 . The peak rhTPO levels ranged from a 10-fold to a 90-fold increase over the baseline. Trough rhTPO and interdose trough levels were 2.3-10 times greater than baseline levels ( Figure 1 ). Maximum mean concentration (C max ) increased with dose except for the 0.6 g/kg every third day schedule. C max was observed at the first sampling (5 min after bolus administration) in most subjects, and time of maximum concentration (T max ) ranged from 5 min to 4 h. With daily dosing, significant accumulation of TPO was not observed although modest increase from trough levels were noted (Figure 2 ). Systemic clearance (Cl) estimates ranged from 0.18 to 4.9 ml/h/kg and appeared to increase with increasing rhTPO dose until reaching a plateau at 2.4-4.8 ᒊg/kg. The terminal half-life (t . ) ranged from 21.4 to 637 h; mean values for those subjects receiving 0.3 or 0.6 g/kg were largely inflated by two patients with t . values of Ͼ600 and Ͼ200 h. At doses у1.2 g/kg, the mean t . was approximately 38 h. The area under the concentration × time curve extrapolated to infinity (AUC inf ) was estimated using 72 h (AUC 0-72 ) of observations, but since the decline in rhTPO concentration was not monoexponential, these results should be interpreted with caution.
In patients receiving 0.6 g/kg daily for up to 21 doses, mean C max was 13.0 (±4.11) and 36.5 (±8.37) ng/ml at day 1 and day 19, respectively. As shown in Figure 2 , rhTPO concentrations did not appear to have reached a plateau by the last rhTPO administration (day 19 or 21).
Hematologic recovery
All 33 patients in this trial developed severe thrombocytopenia (Ͻ20 000/l) and received at least two platelet transfusions. The median number of platelet transfusions per patient was 7 (range, 2-20) without any apparent effect of rhTPO dose or schedule ( Table 3 ). The median last day of platelet transfusion was day 16 (range, 8-37) across all doses and schedules. The median day to platelet recovery by definition 1 was 19 (range, . Recovery of platelet count by this definition by rhTPO dose is demonstrated in Figure 3 . The median day to platelet recovery by the more stringent definition 2 was 18 (range, 9-41). Recovery of platelet count by this definition by rhTPO dose is demonstrated in Figure 4 . No dose-related or schedule effect on the time to platelet recovery was apparent. Subjects receiving 2.4 g/kg every third day of rhTPO had the shortest platelet recovery times with respect to all definitions. Subjects receiving 1.2 g/kg every third day of rhTPO had some of the longest recovery times with respect to all definitions.
The median day to platelet recovery to у50 000/l and у100 000/l were 23 (range, 12-62) days and 26 (range, 15-62+) days, respectively. There were suggestions of faster recoveries to у50 000/l and у100 000/l favoring higher doses and the daily dosing schedule (3.5-5 day difference to у50 000/l and 8-day difference у100 000/l), although these did not reach statistical significance with P = 0.41 and P = 0.16, respectively.
Sixteen patients received marrow transplants with low CD34 + cells numbers (median 1.3 × 10 6 CD34 + /kg, range, 0-2.5) and therefore were felt to be at risk for delayed recovery. However, there was no delay in count recovery C max = maximum concentration; Cl = systemic clearance; V SS = volume of distribution at steady state; t . = terminal half-life; AUC 0-72 = area under the concentration × time curve from 0 to 72 h after dosing; AUC inf = area under the concentration × time curve extrapolated to infinity. Mean serum rhTPO levels in (ng/ml) measured by the rhTPO MPL assay in hours after first rhTPO infusion by daily dosing regimen of 0.6 g/kg.
Table 3
Results of dose levels of rhTPO on platelet recovery to Ͼ20 000/l Days post-transplant Platelet recovery probability rhTPO q3d×10 @0.3 g/kg (n = 7) rhTPO q3d×10 @0.6 g/kg (n = 7) rhTPO q3d×10 @1.2 g/kg (n = 7) rhTPO q3d×10 @2.4 g/kg (n = 3) rhTPO q3d×10 @4.8 g/kg (n = 6) rhTPO qd×21 @0. Figure 4 Day after marrow infusion to recovery of unsupported platelet count (Ͼ20 000/l) by rhTPO dosing regimen with recovery defined as the first of у2 consecutive days of an untransfused platelet count Ͼ20 000/l with the second count being greater than or equal to the preceding value (definition 2).
for this subset, in whom the median day to platelet recovery to у20 000/l (stringent definition 2) was day 15 (range, .
The median time to neutrophil recovery to у500/l and у1500/l was 12 days (range, 10-28) and 14 days (range, 11-31), respectively. There was no evidence of either a dose-dependent enhancement or delay of neutrophil recovery across any of the rhTPO dose groups. For each patient, a median of four red blood cell transfusions were adminis-tered (range, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Similarly, the number of red blood cell transfusion was not related to the dose or administration schedule of rhTPO.
Discussion
In this report, a c-mpl ligand (rhTPO) was studied after ABMT. The primary objective of this phase I trial was to evaluate the safety and tolerance of escalating doses of rhTPO in patients undergoing ABMT for breast cancer concomitantly receiving the myeloid growth factor, G-CSF. Although there were preliminary data suggesting that rhTPO was safe in combination with G-CSF, synergistic toxicities were a concern with the use of these lineage-specific cytokines. 9, 34 In this study, rhTPO was shown to be safe, since all severe adverse events were those anticipated in patients undergoing high-dose therapy followed by ABMT. One patient developed severe asthenia felt possibly related to the study drug, though this event is also common place after high-dose therapy. Therefore, substantial sideeffects were not observed and no dose-limiting toxicity was noted. Neutralizing antibodies to rhTPO were not detected in any patient at any time point.
In our trial, all doses of rhTPO resulted in an equivalent time course of platelet and neutrophil recovery. Since there was no evidence of an adverse effect on neutrophil recovery, with the exception of one patient who may have demonstrated human herpes virus 6-related pancytopenia, the potential of stem cell competition by one cytokine over another was excluded.
Without a concurrent control group, the absolute effect on platelet recovery can only be surmised by comparison with historical controls. Bernstein et al 11 in a large retrospective study of thrombocytopenia after transplantation, reported in a small cohort of patients that the time to platelet recovery after ABMT as 40 days (95% confidence interval of 27-49). That report included all types of diseases undergoing ABMT, but still should be valid for comparison since disease does not directly correlate with hematopoietic recovery after ABMT. In our data, using a similar stringent definition, the overall median time to platelet recovery was 18 days. While such comparison must be made very cautiously, platelet recovery in this study, appeared to be more rapid when compared with ABMT without rhTPO. The results in our trial are also quite similar to those reported with the pegylated megakaryocyte growth and development factor. 35 In the report of Bernstein et al, 11 the recovery of platelets after PBSCT was 13 days (95% confidence interval of 12-13). Our study in recipients of ABMT with rhTPO reports a recovery which compares favorably, although is still delayed. Without direct comparison, this must also be viewed very cautiously considering the variable count increment after platelet transfusion potentially obscuring the earliest time to platelet recovery, as well as small differences in time intervals.
The fact that there was no apparent dose-response effect in this small phase I study may indicate that platelet recovery was not impacted by rhTPO or that at all doses resulted in equivalent thrombopoietic activity with inadequate power to detect inter-dose differences. Alternatively, larger doses of rhTPO or modification of administration method or schedule could still prove effective. Inference about further rhTPO dose augmentation to increase response may be extrapolated from the pharmacokinetic data. Our study observed high peak (post-dose) and trough levels (prior to the next dose) compared with baseline with similar levels measured in patients with severe thrombocytopenia due to diminished production. [36] [37] [38] These observations demonstrating substantial rhTPO levels make it unlikely that even larger doses or schedule modification would be more beneficial. Definitive efficacy will require phase II and III studies designed to primarily test for platelet recovery. Which dose of rhTPO one would consider for future trials is not clearly defined since our trial did not demonstrate toxicity or any pronounced dose effect. Considering the above facts, a dose in the mid-range, such as 2.4 g/kg, would be reasonable for further evaluation.
Interleukin 11 (oprelvekin, Neumega; Genentics Institute, Cambridge, MA, USA) has been approved by the US Food and Drug Administration for the secondary prophylaxis of thrombocytopenia associated with myelosuppressive chemotherapy. Its use has been modest because of observed side-effects. 39 The effects of interleukin 11 on thrombocytopenia after hematopoietic stem cell transplantation have also been published. 40 In that report, 80 women with breast cancer were randomized to placebo or one of two doses of oprelvekin after ABMT and PBSCT. The median time to platelet transfusion independence was similar between the three groups, though there were trends to fewer platelet transfusion events and to a lower incidence of failure to engraft platelets by day 30 in the oprelvekintreated groups.
The most potent cytokine for platelet recovery in preclinical trials is c-MPL ligand. 41 Thus far, only one other report of a c-mpl ligand, pegylated megakaryocyte growth and development factor (Peg-MGDF; Amgen, Thousand Oaks, CA, USA) has reported results after ABMT. 35 Beveridge randomized 50 patients to either placebo or 5 or 10 g/kg/day of Peg-MGDF and noted a 6-day reduction in the time to platelet recovery (from 24 to 18 days) between placebo and the higher dose level, as well as a 7-day decrease in the duration of profound thrombocytopenia and a 45% decrease in platelet transfusion events (though the latter two did not reach statistical significance). It is currently accepted that the day of platelet recovery after stem cell transplantation is related to the dose of CD34 + cells/kg body weight infused, with recoveries tending to be more rapid with cell doses exceeding 2.5 × 10 6 CD34 + /kg.
11
In that report, the median CD34 + cell count in the marrow harvest was 1.6 × 10 6 /kg. In our study, patients with low CD34 + cell counts had similar and rapid recovery compared to the entire group.
In summary, rhTPO in combination with G-CSF was found to be safe and well-tolerated in patients undergoing myeloablative therapy followed by ABMT rescue. No evidence of adverse interaction with G-CSF (stem cell steal) was noted. When compared with historical ABMT controls, rhTPO at all studied doses and schedules, may have enhanced the recovery from thrombocytopenia and approached that achieved after PBSCT, although no con-clusions about efficacy can be made. Further investigations with larger numbers of patients will be necessary to evaluate efficacy and define a suitable dose for further study. Nevertheless, this trial demonstrates the safety of rhTPO in the clinical setting of high-dose chemotherapy followed by ABMT for patients with breast cancer.
